Login / Signup

Intraperitoneal injection of Desferal® alleviated the age-related bone loss and senescence of bone marrow stromal cells in rats.

Lingxian YiYue JuYing HeXiushan YinYe XuTujun Weng
Published in: Stem cell research & therapy (2021)
The current study suggested that Desferal®, an iron-chelating agent, could alleviate age-related bone loss in middle-aged rats. Meanwhile, we found that short-term intraperitoneal injection of Desferal® partly rejuvenate BMSCs from aged rats. Overall, we demonstrated a novel role of Desferal® in rejuvenating aged BMSCs and preventing age-related bone loss.
Keyphrases
  • bone loss
  • bone marrow
  • middle aged
  • mesenchymal stem cells
  • dna damage